Welcome to Update+, a short tour around the grounds of investment in the big disruptive trends that are driving business. This month, Investment Analyst Tom Keir discusses Moderna’s breakthrough cancer vaccine Intismeran and how Loftus Peak investment process was able to identify this opportunity ahead of its clinical trial announcement.
Share this Post

